<DOC>
	<DOCNO>NCT01140542</DOCNO>
	<brief_summary>This study proof concept study confirm standardize manner therapeutic efficacy roflumilast type 2 diabetes mellitus patient .</brief_summary>
	<brief_title>Efficacy 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks Patients With Diabetes Mellitus Type 2 . A Double Blind , Parallel Group , Proof Concept Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>give write informed consent patient diagnosis type 2 diabetes accord American Diabetes Association ( ADA ) criteria inadequately control diet exercise alone HbA1c baseline : ≥7.5 percent 8.5 percent ( 9 percent Mexico , Ukraine Romania ) BMI ≥26 ≤35 kg/m2 willingness patient check his/her blood glucose equipment provide sponsor treatment phase case hypo/hyperglycemia episodes willingness adhere physician 's advise comply diet exercise Main patient diagnose type 1 diabetes diabetes secondary pancreatitis resection pancreas patient diagnosed hemoglobinopathy , hemolytic anemia disease interfere HbA1c measurement noneuthyroid patient patient noncontrolled hypo hyperthyroidism report gain loss 5 percent body weight within last 2 month prior V0 treatment diabetes medication prior V0 treatment weightloss medication within 3 month prior V0 treatment allow medication nutrition additives clinically relevant abnormal laboratory value suggest unknown disease require clinical evaluation ( assessed investigator ) clinically significant cardiac abnormality ( diagnose clinically , Xray/ECG ) relate type 2 diabetes mellitus require evaluation participation clinical study study medication weight loss type 2 diabetes Patients randomize 2 week baseline period , follow criterion fulfil : judge clinically stable tablet compliance ≥80 percent ≤125 percent HbA1c range 7.5 percent 8.5 percent ( 9 percent Mexico , Ukraine Romania ) test V0 central laboratory</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
	<keyword>Roflumilast</keyword>
</DOC>